Screener
Exelixis EXEL Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Exelixis in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: Exelixis’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q3 2026
- Accession
- 0000939767-26-000098
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accrued clinical trial liabilities | 59,767 | 65,742 |
| Rebates and fees due to customers | 66,711 | 59,896 |
| Accrued collaboration liabilities | 25,096 | 22,783 |
| Other current liabilities | 102,662 | 125,382 |
| Total current liabilities | 361,927 | 405,644 |
| Non-current operating lease liabilities | 165,929 | 173,038 |
| Other non-current liabilities | 122,616 | 104,422 |
| Total liabilities | 650,472 | 683,104 |
Item 1. Financial Statements.
FAQ
- What is Exelixis's accrued expenses?
- Exelixis (EXEL) reported accrued expenses of $102.66M in Q2 2026.
- How has Exelixis's accrued expenses changed year-over-year?
- Exelixis's accrued expenses increased by 1.3% year-over-year, from $101.37M to $102.66M.
- What is the long-term trend for Exelixis's accrued expenses?
- Over 5 years (2020 to 2025), Exelixis's accrued expenses has grown at a 23.0% compound annual growth rate (CAGR), from $44.45M to $125.38M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Exelixis's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude